<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39355257</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Identifying immune checkpoints on dysregulated T-cells as prognostic biomarkers for multiple myeloma patients with COVID-19.</ArticleTitle><Pagination><StartPage>1448653</StartPage><MedlinePgn>1448653</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1448653</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1448653</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Broad T cell phenotypic alterations and potential dysfunctions were prominent in COVID-19. There are few and inconclusive data about the role of immune checkpoints for T cell exhaustion/activation during SARS-CoV-2 infection in multiple myeloma (MM) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We tested T cell subsets and immune checkpoints in 177 MM patients with COVID-19, as well as in 32 healthy infected controls and 42 uninfected MM patients. The percentage of CD4+ and CD8+ subpopulation and immune checkpoints (PD-1, TIGIT, TIM-3, LAG-3, CTLA-4, OX40, and 4-1BB) were evaluated by flow cytometry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We have found that pronounced lymphopenia and inverted CD4/CD8 ratio in severe COVID-19 patients were especially developed within the first month after infection. And T cell subset dysregulation was persistent in severe patients recovering from SARS-CoV-2 infection. Immune checkpoints on CD4+ T cells were variable and uncorrelated with the level of adaptive immunity, while the proportion of CD4+ T cells was positively correlated with humoral immune response. PD-1 and TIGIT on CD8+ T cells were significantly elevated in severe patients and sustained for more than 2 months, which was associated with impaired cellular immune function. Moreover, exhausted molecules PD-1 and TIGIT on T cells were reduced in immunotherapy patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The prolonged T cell dysregulation after severe SARS-CoV-2 infection highlights the close surveillance from reinfection in MM patients even during convalescence. PD-1 and TIGIT on CD8+ T cells could be important prognostic factors to stratify prognosis in MM patients with COVID-19. Moreover, immunotherapy may downregulate the expression of exhausted checkpoints PD-1 and TIGIT, leading to T cell overactivation and severe COVID-19.</AbstractText><CopyrightInformation>Copyright © 2024 Li, He, Zhang, Li, Jin, Song, Liu, Wang and Zhuang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Ziping</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>He</LastName><ForeName>Huiwen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fujing</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Haolong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Xianghong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yuhang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shuangjiao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Junling</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082102">Immune Checkpoint Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009101" MajorTopicYN="Y">Multiple Myeloma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082102" MajorTopicYN="N">Immune Checkpoint Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">immune checkpoints</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">multiple myeloma</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39355257</ArticleId><ArticleId IdType="pmc">PMC11442272</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1448653</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shrager SH, Kiel C. SnapShot: APC/T cell immune checkpoints. Cell. (2020) 183:1142–1142.e1. doi: 10.1016/j.cell.2020.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.007</ArticleId><ArticleId IdType="pubmed">33186524</ArticleId></ArticleIdList></Reference><Reference><Citation>Asashima H, Mohanty S, Comi M, Ruff WE, Hoehn KB, Wong P, et al. . PD-1highCXCR5-CD4+ peripheral helper T cells promote CXCR3+ plasmablasts in human acute viral infection. Cell Rep. (2023) 42:111895. doi: 10.1016/j.celrep.2022.111895</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111895</ArticleId><ArticleId IdType="pmc">PMC9806868</ArticleId><ArticleId IdType="pubmed">36596303</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mterin MA, Alsalman A, Elkord E. Inhibitory immune checkpoint receptors and ligands as prognostic biomarkers in COVID-19 patients. Front Immunol. (2022) 13:870283. doi: 10.3389/fimmu.2022.870283</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.870283</ArticleId><ArticleId IdType="pmc">PMC9008255</ArticleId><ArticleId IdType="pubmed">35432324</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbatino F, Conti V, Franci G, Sellitto C, Manzo V, Pagliano P, et al. . PD-L1 dysregulation in COVID-19 patients. Front Immunol. (2021) 12:695242. doi: 10.3389/fimmu.2021.695242</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.695242</ArticleId><ArticleId IdType="pmc">PMC8215357</ArticleId><ArticleId IdType="pubmed">34163490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. . Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. (2020) 17:533–5. doi: 10.1038/s41423-020-0402-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0402-2</ArticleId><ArticleId IdType="pmc">PMC7091858</ArticleId><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. . Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. (2020) 17:541–3. doi: 10.1038/s41423-020-0401-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0401-3</ArticleId><ArticleId IdType="pmc">PMC7091621</ArticleId><ArticleId IdType="pubmed">32203186</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahbaz S, Xu L, Sligl W, Osman M, Bozorgmehr N, Mashhouri S, et al. . The quality of SARS-coV-2-specific T cell functions differs in patients with mild/moderate versus severe disease, and T cells expressing coinhibitory receptors are highly activated. J Immunol. (2021) 207:1099–111. doi: 10.4049/jimmunol.2100446</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100446</ArticleId><ArticleId IdType="pubmed">34312258</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, Boppana S, Perez MD, Sarkar S, Lowman KE, Qin K, et al. . Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. J Clin Invest. (2021) 131:e140491. doi: 10.1172/JCI140491</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140491</ArticleId><ArticleId IdType="pmc">PMC7773371</ArticleId><ArticleId IdType="pubmed">33119547</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zhong M, Zhang E, Hong K, Yang Q, Zhou D, et al. . Broad phenotypic alterations and potential dysfunction of lymphocytes in individuals clinically recovered from COVID-19. J Mol Cell Biol. (2021) 13:197–209. doi: 10.1093/jmcb/mjab014</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjab014</ArticleId><ArticleId IdType="pmc">PMC7989217</ArticleId><ArticleId IdType="pubmed">33751111</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. (2023) 73:275–85. doi: 10.3322/caac.21771</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21771</ArticleId><ArticleId IdType="pubmed">36627265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. . COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. (2020) 21:1309–16. doi: 10.1016/S1470-2045(20)30442-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30442-3</ArticleId><ArticleId IdType="pmc">PMC7444972</ArticleId><ArticleId IdType="pubmed">32853557</ArticleId></ArticleIdList></Reference><Reference><Citation>Available online at: https://www.gov.cn/zhengce/zhengceku/2023/01/06/5735343/files/5844ce04246b431dbd322d8ba10afb48.pdf. (Accessed July 5, 2023).</Citation></Reference><Reference><Citation>Fendler A, Au L, Shepherd STC, Byrne F, Cerrone M, Boos LA, et al. . Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer. (2021) 2:1321–37. doi: 10.1038/s43018-021-00275-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-021-00275-9</ArticleId><ArticleId IdType="pubmed">35121900</ArticleId></ArticleIdList></Reference><Reference><Citation>Schub D, Klemis V, Schneitler S, Mihm J, Lepper PM, Wilkens H, et al. . High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. JCI Insight. (2020) 5:e142167. doi: 10.1172/jci.insight.142167</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.142167</ArticleId><ArticleId IdType="pmc">PMC7605520</ArticleId><ArticleId IdType="pubmed">32937615</ArticleId></ArticleIdList></Reference><Reference><Citation>Varchetta S, Mele D, Oliviero B, Mantovani S, Ludovisi S, Cerino A, et al. . Unique immunological profile in patients with COVID-19. Cell Mol Immunol. (2021) 18:604–12. doi: 10.1038/s41423-020-00557-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00557-9</ArticleId><ArticleId IdType="pmc">PMC7557230</ArticleId><ArticleId IdType="pubmed">33060840</ArticleId></ArticleIdList></Reference><Reference><Citation>De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, et al. . Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. (2020) 11:3434. doi: 10.1038/s41467-020-17292-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17292-4</ArticleId><ArticleId IdType="pmc">PMC7338513</ArticleId><ArticleId IdType="pubmed">32632085</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. . Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. (2020) 11:827. doi: 10.3389/fimmu.2020.00827</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00827</ArticleId><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Rha MS, Jeong HW, Ko JH, Choi SJ, Seo IH, Lee JS, et al. . PD-1-expressing SARS-coV-2-specific CD8+ T cells are not exhausted, but functional in patients with COVID-19. Immunity. (2021) 54:44–52.e3. doi: 10.1016/j.immuni.2020.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.12.002</ArticleId><ArticleId IdType="pmc">PMC7834198</ArticleId><ArticleId IdType="pubmed">33338412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020) 395:1033–4. doi: 10.1016/S0140-6736(20)30628-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong Y, Wang Y, Wu X, Han J, Li G, Hua M, et al. . Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduct Target Ther. (2020) 5:192. doi: 10.1038/s41392-020-00308-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00308-2</ArticleId><ArticleId IdType="pmc">PMC7475713</ArticleId><ArticleId IdType="pubmed">32895366</ArticleId></ArticleIdList></Reference><Reference><Citation>Schönrich G, Raftery MJ. CD1-restricted T cells during persistent virus infections: “Sympathy for the devil. Front Immunol. (2018) 9:545. doi: 10.3389/fimmu.2018.00545</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00545</ArticleId><ArticleId IdType="pmc">PMC5868415</ArticleId><ArticleId IdType="pubmed">29616036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>